MedPath

Hypopituitarism in patients after subarachnoid hemorrhage: Screening and treatment.

Recruiting
Conditions
Hypopituitarism in patients after subarachnoid hemorrhage
Registration Number
NL-OMON23702
Lead Sponsor
erasmus medical centre
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
120
Inclusion Criteria

1. Subarachnoid hemorrhage;

2. Signed and dated informed consent document.

Exclusion Criteria

Subjects with any of the following items will be excluded from the study:

1. Any hypothalamic/pituitary disease diagnosed prior to SAH;

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. To determine the prevalence of hypopituitarism in patients after SAH;<br /><br>2. To identify neurological parameters that predict hypopituitarism after SAH;<br /><br>3. To determine the value of a Ghrelin test shortly after SAH, to identify subjects with GHD.<br>
Secondary Outcome Measures
NameTimeMethod
1. To determine the impact of hypopituitarism on physical functioning, activity pattern and participation;<br /><br>2. To evaluate the effect of GH replacement on residual functional physical fitness, fatigue and quality of life.<br>
© Copyright 2025. All Rights Reserved by MedPath